Cadrenal completes FDA End-of-Phase 2 meeting; gets guidance for Phase 3 pivotal trial of CAD-1005 in HIT

Cadrenal Therapeutics, Inc.

Phase 2 data showed >25% absolute reduction in thrombotic events when CAD-1005 added to standard anticoagulant therapy.
Planned Phase 3 trial: randomized, blinded, placebo-controlled; ~120 patients at up to 50 sites worldwide.
Primary endpoint: incidence of new or worsening thrombotic events (centrally adjudicated) in SRA-confirmed HIT patients.
Projected NDA submission in 2029; first randomized, blinded, placebo-controlled registration trial in HIT.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.